Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors
Background This study aimed to identify potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and further probe the prognostic implications of CDKN2A mutations, particularly within a subset receiving immunotherapy. Methods In this retrospective s...
Saved in:
Published in | Frontiers in oncology Vol. 13; p. 1276009 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
23.10.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
This study aimed to identify potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and further probe the prognostic implications of CDKN2A mutations, particularly within a subset receiving immunotherapy.
Methods
In this retrospective single-center study, we evaluated the next-generation sequencing (NGS) data from Foundation Medicine (FM) for patients with recurrent or metastatic HNSCC between January 1, 2019, and December 31, 2021. Patients were stratified based on CDKN2A loss-of-function (LOF) versus wild-type (WT) categorizations, with a focused subgroup analysis on those administered immunotherapy.
Results
The study encompassed 77 patients, of which 62 had undergone immunotherapy. The median duration of follow-up was 22.6 months. For the CDKN2A LOF group, the median overall survival (OS) was 16.5 months, contrasted with 30.0 months in the CDKN2A WT group (
P
=0.014). Notably, female gender (hazard ratio [HR]=4.526, 95% confidence interval [CI]: 1.934-10.180,
P
=0.0003) and CDKN2A LOF (HR=2.311, 95% CI: 1.156-4.748,
P
=0.019) emerged as independent risk factors for mortality in patients with recurrent or metastatic HNSCC. Within the immunotherapy subset, the median OS was 11.7 months for the CDKN2A LOF group, and 22.5 months for the CDKN2A WT group (
P
=0.017). Further, the female gender (HR=4.022, 95% CI: 1.417-10.710,
P
=0.006), CDKN2A LOF (HR=4.389, 95% CI: 1.782-11.460,
P
=0.002), and a combined positive score below 1 (HR=17.20, 95% CI: 4.134-79.550,
P
<0.0001) were identified as significant predictors of mortality among patients with recurrent or metastatic HNSCC receiving immunotherapy.
Conclusion
Alterations manifesting as LOF in the CDKN2A gene stand as robust indicators of unfavorable survival outcomes in HNSCC patients, including the subset that underwent immunotherapy. |
---|---|
AbstractList | Background
This study aimed to identify potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and further probe the prognostic implications of CDKN2A mutations, particularly within a subset receiving immunotherapy.
Methods
In this retrospective single-center study, we evaluated the next-generation sequencing (NGS) data from Foundation Medicine (FM) for patients with recurrent or metastatic HNSCC between January 1, 2019, and December 31, 2021. Patients were stratified based on CDKN2A loss-of-function (LOF) versus wild-type (WT) categorizations, with a focused subgroup analysis on those administered immunotherapy.
Results
The study encompassed 77 patients, of which 62 had undergone immunotherapy. The median duration of follow-up was 22.6 months. For the CDKN2A LOF group, the median overall survival (OS) was 16.5 months, contrasted with 30.0 months in the CDKN2A WT group (
P
=0.014). Notably, female gender (hazard ratio [HR]=4.526, 95% confidence interval [CI]: 1.934-10.180,
P
=0.0003) and CDKN2A LOF (HR=2.311, 95% CI: 1.156-4.748,
P
=0.019) emerged as independent risk factors for mortality in patients with recurrent or metastatic HNSCC. Within the immunotherapy subset, the median OS was 11.7 months for the CDKN2A LOF group, and 22.5 months for the CDKN2A WT group (
P
=0.017). Further, the female gender (HR=4.022, 95% CI: 1.417-10.710,
P
=0.006), CDKN2A LOF (HR=4.389, 95% CI: 1.782-11.460,
P
=0.002), and a combined positive score below 1 (HR=17.20, 95% CI: 4.134-79.550,
P
<0.0001) were identified as significant predictors of mortality among patients with recurrent or metastatic HNSCC receiving immunotherapy.
Conclusion
Alterations manifesting as LOF in the CDKN2A gene stand as robust indicators of unfavorable survival outcomes in HNSCC patients, including the subset that underwent immunotherapy. BackgroundThis study aimed to identify potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and further probe the prognostic implications of CDKN2A mutations, particularly within a subset receiving immunotherapy.MethodsIn this retrospective single-center study, we evaluated the next-generation sequencing (NGS) data from Foundation Medicine (FM) for patients with recurrent or metastatic HNSCC between January 1, 2019, and December 31, 2021. Patients were stratified based on CDKN2A loss-of-function (LOF) versus wild-type (WT) categorizations, with a focused subgroup analysis on those administered immunotherapy.ResultsThe study encompassed 77 patients, of which 62 had undergone immunotherapy. The median duration of follow-up was 22.6 months. For the CDKN2A LOF group, the median overall survival (OS) was 16.5 months, contrasted with 30.0 months in the CDKN2A WT group (P=0.014). Notably, female gender (hazard ratio [HR]=4.526, 95% confidence interval [CI]: 1.934-10.180, P=0.0003) and CDKN2A LOF (HR=2.311, 95% CI: 1.156-4.748, P=0.019) emerged as independent risk factors for mortality in patients with recurrent or metastatic HNSCC. Within the immunotherapy subset, the median OS was 11.7 months for the CDKN2A LOF group, and 22.5 months for the CDKN2A WT group (P=0.017). Further, the female gender (HR=4.022, 95% CI: 1.417-10.710, P=0.006), CDKN2A LOF (HR=4.389, 95% CI: 1.782-11.460, P=0.002), and a combined positive score below 1 (HR=17.20, 95% CI: 4.134-79.550, P<0.0001) were identified as significant predictors of mortality among patients with recurrent or metastatic HNSCC receiving immunotherapy.ConclusionAlterations manifesting as LOF in the CDKN2A gene stand as robust indicators of unfavorable survival outcomes in HNSCC patients, including the subset that underwent immunotherapy. |
Author | Zhao, Wei Guo, Ye Tang, Wenbo Xue, Junli Zhou, Jiuli Lin, Fengjuan Li, Qun Ge, Xiaoxiao Xue, Liqiong |
AuthorAffiliation | Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University , Shanghai , China |
AuthorAffiliation_xml | – name: Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University , Shanghai , China |
Author_xml | – sequence: 1 givenname: Liqiong surname: Xue fullname: Xue, Liqiong – sequence: 2 givenname: Wenbo surname: Tang fullname: Tang, Wenbo – sequence: 3 givenname: Jiuli surname: Zhou fullname: Zhou, Jiuli – sequence: 4 givenname: Junli surname: Xue fullname: Xue, Junli – sequence: 5 givenname: Qun surname: Li fullname: Li, Qun – sequence: 6 givenname: Xiaoxiao surname: Ge fullname: Ge, Xiaoxiao – sequence: 7 givenname: Fengjuan surname: Lin fullname: Lin, Fengjuan – sequence: 8 givenname: Wei surname: Zhao fullname: Zhao, Wei – sequence: 9 givenname: Ye surname: Guo fullname: Guo, Ye |
BookMark | eNpVkk1vEzEQhleoSJTQH8DNRy4J_so6e0JV-KqoygUkbtasPU7c7tqp7a3oL-Rv4W0iRH2xNX7nGc_4fd2chRiwad4yuhJi0713MZgVp1ysGFctpd2L5pxzIZedFL_O_ju_ai5yvqV1tWvKqDhv_tzg77LcYcAExcdAMt5PGIwPO-IthuKdx0y2H7_d8EsCQznpMoFMDinuQszFG9L7OEK6w5SJDyShmVKq2SQmMmKBXGBW7REsgWBJQHNH8v0EY5wyMTgMxECqVSulYtHG0QcIZXicWegfnt4zjlNAYvY1-RB9pfuw970vMeU3zUsHQ8aL075ofn7-9GP7dXn9_cvV9vJ6aaQUZckNY4iux84q5mxPrZKSMikkX3OwbWtY5xBlx3rBRN_y3lrabVp0SklnjVg0V0eujXCrD8nXrh91BK-fAjHtNKTa6oCagxTCGUUtQ6lkB0xiLx2qtTEdcFdZH46sw9SPaE2dV4LhGfT5TfB7vYsPmtGWK9ZuKuHdiZBi_bZc9OjzPE0IWAer-WajpFrP1lg07Cg1Keac0P2rw6ieXaRnF-lZqk8uEn8Bt8jFvw |
CitedBy_id | crossref_primary_10_3389_fimmu_2024_1428529 crossref_primary_10_3390_biomedicines12030696 crossref_primary_10_3389_fonc_2024_1364958 |
Cites_doi | 10.1016/j.coms.2018.06.004 10.1002/hed.25075 10.1016/j.ebiom.2016.04.017 10.1016/j.annonc.2020.02.017 10.1002/hed.25580 10.1152/ajpheart.00109.2016 10.1016/j.coms.2018.06.001 10.3389/fonc.2018.00095 10.1158/1078-0432.CCR-21-0575 10.1136/jmedgenet-2011-100563 10.1038/nature25501 10.1159/000494473 10.1016/j.xcrm.2021.100411 10.1001/jamaoncol.2022.1846 10.1056/NEJMra1715715 10.1056/NEJMoa1602252 10.3322/caac.21660 10.1016/j.oraloncology.2017.07.030 10.1016/j.coms.2014.01.001 10.1002/lary.23308 10.1200/JCO.2017.77.0388 10.1038/nbt.2696 10.1093/nar/gkn653 10.3390/cancers13112709 10.1038/nature14129 10.1038/s41598-021-99524-1 10.1001/jamaoto.2018.4513 10.1093/annonc/mdv109 10.3390/cancers11040445 10.2147/CMAR.S187780 10.1016/S1470-2045(16)30066-3 10.3390/cancers12092359 10.1371/journal.pone.0230306 10.1158/1078-0432.CCR-21-4316 10.3389/fgene.2022.1036408 10.1038/s41467-020-14987-6 10.3389/fimmu.2019.01756 10.1002/hed.25366 10.1158/1078-0432.CCR-16-2128 10.1016/j.annonc.2020.07.011 |
ContentType | Journal Article |
Copyright | Copyright © 2023 Xue, Tang, Zhou, Xue, Li, Ge, Lin, Zhao and Guo 2023 Xue, Tang, Zhou, Xue, Li, Ge, Lin, Zhao and Guo |
Copyright_xml | – notice: Copyright © 2023 Xue, Tang, Zhou, Xue, Li, Ge, Lin, Zhao and Guo 2023 Xue, Tang, Zhou, Xue, Li, Ge, Lin, Zhao and Guo |
DBID | AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fonc.2023.1276009 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2234-943X |
EndPage | 1276009 |
ExternalDocumentID | oai_doaj_org_article_2a433fc70d1e4749a14eb4fe75cc9a2f 10_3389_fonc_2023_1276009 |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EJD EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW ITC KQ8 M48 M~E OK1 PGMZT RNS RPM 7X8 5PM |
ID | FETCH-LOGICAL-c443t-2c11eefbe9d71fdb0d74401434252ad66c19fee491b313b62bdd0986ef774fdc3 |
IEDL.DBID | RPM |
ISSN | 2234-943X |
IngestDate | Thu Jul 04 21:05:05 EDT 2024 Tue Sep 17 21:29:30 EDT 2024 Fri Aug 16 01:20:02 EDT 2024 Fri Aug 23 01:18:06 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c443t-2c11eefbe9d71fdb0d74401434252ad66c19fee491b313b62bdd0986ef774fdc3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors have contributed equally to this work Edited by: Tong-Chuan He, University of Chicago Medicine, United States Reviewed by: Yuanping Xiong, First Affiliated Hospital of Nangchang University, China; Wenping Luo, Southwest University, China; Fugui Zhang, Stomatological Hospital of Chongqing Medical University, China |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627168/ |
PQID | 2887475202 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_2a433fc70d1e4749a14eb4fe75cc9a2f pubmedcentral_primary_oai_pubmedcentral_nih_gov_10627168 proquest_miscellaneous_2887475202 crossref_primary_10_3389_fonc_2023_1276009 |
PublicationCentury | 2000 |
PublicationDate | 2023-10-23 |
PublicationDateYYYYMMDD | 2023-10-23 |
PublicationDate_xml | – month: 10 year: 2023 text: 2023-10-23 day: 23 |
PublicationDecade | 2020 |
PublicationTitle | Frontiers in oncology |
PublicationYear | 2023 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Yu (B9) 2019; 41 Ferris (B30) 2016; 375 Liu (B41) 2021; 2 Cohen (B2) 2018; 30 Cancer Genome Atlas (B20) 2015; 517 Zhou (B17) 2018; 50 Wang (B38) 2019; 10 Mascarella (B13) 2019; 145 Chen (B16) 2018; 8 Mariathasan (B39) 2018; 554 Vossen (B26) 2019; 11 Lassig (B12) 2012; 122 Lamberti (B35) 2020; 31 Mascarella (B8) 2018; 40 Chung (B22) 2015; 26 Hilke (B34) 2020; 12 Seiwert (B31) 2016; 17 Brenner (B33) 2020; 11 Takenaka (B10) 2018; 40 Gutiontov (B36) 2021; 11 Frampton (B14) 2013; 31 Adib (B32) 2021; 27 Balli (B37) 2017; 23 Seeburg (B3) 2018; 30 Jiang (B21) 2019; 11 Harinck (B24) 2012; 49 Schaefer (B19) 2009; 37 Ma (B29) 2018; 36 Chow (B1) 2020; 382 Fan (B28) 2021; 13 B6 Machiels (B7) 2020; 31 Zhang (B15) 2016; 310 DeLeon (B40) 2020; 15 (B4) 2022 Sung (B5) 2021; 71 Vigneswaran (B11) 2014; 26 Padhi (B27) 2017; 73 Zhao (B23) 2016; 8 Fan (B18) 2022; 13 Yu (B42) 2022; 8 Deneka (B25) 2022; 28 |
References_xml | – volume: 30 year: 2018 ident: B3 article-title: Imaging of patients with head and neck cancer: from staging to surveillance publication-title: Oral Maxillofac Surg Clin North Am doi: 10.1016/j.coms.2018.06.004 contributor: fullname: Seeburg – volume: 40 year: 2018 ident: B8 article-title: Neutrophil-to-lymphocyte ratio in head and neck cancer prognosis: A systematic review and meta-analysis publication-title: Head Neck doi: 10.1002/hed.25075 contributor: fullname: Mascarella – volume: 8 year: 2016 ident: B23 article-title: Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer publication-title: EBioMedicine doi: 10.1016/j.ebiom.2016.04.017 contributor: fullname: Zhao – volume: 31 year: 2020 ident: B35 article-title: Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.02.017 contributor: fullname: Lamberti – volume: 41 year: 2019 ident: B9 article-title: Preoperative neutrophil lymphocyte ratio but not platelet lymphocyte ratio predicts survival and early relapse in patients with oral, pharyngeal, and lip cancer publication-title: Head Neck doi: 10.1002/hed.25580 contributor: fullname: Yu – volume: 310 year: 2016 ident: B15 article-title: Inhibition of endothelial nitric oxide synthase decreases breast cancer cell MDA-MB-231 adhesion to intact microvessels under physiological flows publication-title: Am J Physiol Heart Circ Physiol doi: 10.1152/ajpheart.00109.2016 contributor: fullname: Zhang – volume: 30 year: 2018 ident: B2 article-title: Epidemiology and demographics of the head and neck cancer population publication-title: Oral Maxillofac Surg Clin North Am doi: 10.1016/j.coms.2018.06.001 contributor: fullname: Cohen – volume: 8 year: 2018 ident: B16 article-title: CDKN2A copy number loss is an independent prognostic factor in HPV-negative head and neck squamous cell carcinoma publication-title: Front Oncol doi: 10.3389/fonc.2018.00095 contributor: fullname: Chen – volume: 27 year: 2021 ident: B32 article-title: CDKN2A alterations and response to immunotherapy in solid tumors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-21-0575 contributor: fullname: Adib – volume: 49 year: 2012 ident: B24 article-title: Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas publication-title: J Med Genet doi: 10.1136/jmedgenet-2011-100563 contributor: fullname: Harinck – volume: 554 year: 2018 ident: B39 article-title: TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells publication-title: Nature doi: 10.1038/nature25501 contributor: fullname: Mariathasan – volume: 50 year: 2018 ident: B17 article-title: The association and clinical significance of CDKN2A promoter methylation in head and neck squamous cell carcinoma: a meta-analysis publication-title: Cell Physiol Biochem doi: 10.1159/000494473 contributor: fullname: Zhou – volume: 2 start-page: 100411 year: 2021 ident: B41 article-title: Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma publication-title: Cell Rep Med doi: 10.1016/j.xcrm.2021.100411 contributor: fullname: Liu – volume: 8 year: 2022 ident: B42 article-title: Association of low and intermediate combined positive scores with outcomes of treatment with pembrolizumab in patients with recurrent and metastatic head and neck squamous cell carcinoma: secondary analysis of keynote 048 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2022.1846 contributor: fullname: Yu – volume: 382 start-page: 60 year: 2020 ident: B1 article-title: Head and neck cancer publication-title: N Engl J Med doi: 10.1056/NEJMra1715715 contributor: fullname: Chow – volume: 375 year: 2016 ident: B30 article-title: Nivolumab for recurrent squamous-cell carcinoma of the head and neck publication-title: N Engl J Med doi: 10.1056/NEJMoa1602252 contributor: fullname: Ferris – volume: 71 year: 2021 ident: B5 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 contributor: fullname: Sung – volume: 73 start-page: 27 year: 2017 ident: B27 article-title: Role of CDKN2A/p16 expression in the prognostication of oral squamous cell carcinoma publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2017.07.030 contributor: fullname: Padhi – volume: 26 year: 2014 ident: B11 article-title: Epidemiologic trends in head and neck cancer and aids in diagnosis publication-title: Oral Maxillofac Surg Clin North Am doi: 10.1016/j.coms.2014.01.001 contributor: fullname: Vigneswaran – volume: 122 year: 2012 ident: B12 article-title: The effect of smoking on perioperative complications in head and neck oncologic surgery publication-title: Laryngoscope doi: 10.1002/lary.23308 contributor: fullname: Lassig – volume: 36 year: 2018 ident: B29 article-title: Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742) publication-title: J Clin Oncol doi: 10.1200/JCO.2017.77.0388 contributor: fullname: Ma – volume: 31 year: 2013 ident: B14 article-title: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing publication-title: Nat Biotechnol doi: 10.1038/nbt.2696 contributor: fullname: Frampton – volume: 37 year: 2009 ident: B19 article-title: PID: the pathway interaction database publication-title: Nucleic Acids Res doi: 10.1093/nar/gkn653 contributor: fullname: Schaefer – volume: 13 year: 2021 ident: B28 article-title: Prognostic genetic biomarkers based on oncogenic signaling pathways for outcome prediction in patients with oral cavity squamous cell carcinoma publication-title: Cancers (Basel). doi: 10.3390/cancers13112709 contributor: fullname: Fan – volume-title: Head and Neck Cancers. Version 1.2023 year: 2022 ident: B4 – volume: 517 year: 2015 ident: B20 article-title: Comprehensive genomic characterization of head and neck squamous cell carcinomas publication-title: Nature doi: 10.1038/nature14129 contributor: fullname: Cancer Genome Atlas – volume: 11 start-page: 20059 year: 2021 ident: B36 article-title: CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer publication-title: Sci Rep doi: 10.1038/s41598-021-99524-1 contributor: fullname: Gutiontov – volume: 145 year: 2019 ident: B13 article-title: Evaluation of a preoperative adverse event risk index for patients undergoing head and neck cancer surgery publication-title: JAMA Otolaryngol Head Neck Surg doi: 10.1001/jamaoto.2018.4513 contributor: fullname: Mascarella – volume: 26 year: 2015 ident: B22 article-title: Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing publication-title: Ann Oncol doi: 10.1093/annonc/mdv109 contributor: fullname: Chung – volume: 11 year: 2019 ident: B26 article-title: Genetic factors associated with a poor outcome in head and neck cancer patients receiving definitive chemoradiotherapy publication-title: Cancers (Basel) doi: 10.3390/cancers11040445 contributor: fullname: Vossen – volume: 11 year: 2019 ident: B21 article-title: Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma publication-title: Cancer Manag Res doi: 10.2147/CMAR.S187780 contributor: fullname: Jiang – ident: B6 – volume: 17 year: 2016 ident: B31 article-title: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30066-3 contributor: fullname: Seiwert – volume: 12 year: 2020 ident: B34 article-title: Distinct mutation patterns reveal melanoma subtypes and influence immunotherapy response in advanced melanoma patients publication-title: Cancers (Basel) doi: 10.3390/cancers12092359 contributor: fullname: Hilke – volume: 15 year: 2020 ident: B40 article-title: Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations publication-title: PloS One doi: 10.1371/journal.pone.0230306 contributor: fullname: DeLeon – volume: 28 year: 2022 ident: B25 article-title: Association of TP53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-21-4316 contributor: fullname: Deneka – volume: 13 year: 2022 ident: B18 article-title: Cuproptosis-associated CDKN2A is targeted by plicamycin to regulate the microenvironment in patients with head and neck squamous cell carcinoma publication-title: Front Genet doi: 10.3389/fgene.2022.1036408 contributor: fullname: Fan – volume: 11 start-page: 1335 year: 2020 ident: B33 article-title: Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours publication-title: Nat Commun doi: 10.1038/s41467-020-14987-6 contributor: fullname: Brenner – volume: 10 year: 2019 ident: B38 article-title: Immune cytolytic activity is associated with genetic and clinical properties of glioma publication-title: Front Immunol doi: 10.3389/fimmu.2019.01756 contributor: fullname: Wang – volume: 40 year: 2018 ident: B10 article-title: Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta-analysis publication-title: Head Neck doi: 10.1002/hed.25366 contributor: fullname: Takenaka – volume: 23 year: 2017 ident: B37 article-title: Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-2128 contributor: fullname: Balli – volume: 31 year: 2020 ident: B7 article-title: Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.07.011 contributor: fullname: Machiels |
SSID | ssj0000650103 |
Score | 2.3871474 |
Snippet | Background
This study aimed to identify potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and further... BackgroundThis study aimed to identify potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and further... |
SourceID | doaj pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database |
StartPage | 1276009 |
SubjectTerms | cyclin-dependent kinase inhibitor 2A head and neck squamous cell carcinoma immunotherapy next-generation sequencing Oncology prognosis |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4imWl4zECSm0fmZ9LIWqAnVPVOrN8mNMo4LT7m6R-IX8LWaSFG1OXLgmke14xvP2N4y9VUXm4JamCegso4Pi8EjZYBtN0CBWZpOGYM7pyp6c6c_n5nyn1RfVhI3wwOPG7cuglSqpPcgCdKtdEBqiLtCalFyQZZC-wuw4U6MMNtTAYExjohfm9ktfCbFQqvdCUjLKzRTRgNc_MzLnJZI7Ouf4Abs_GYv8cFzkQ3YH6iN293RKhz9mv1fkt34bkKNpg_lUGI3qiHd5rAOCDT_6-GUlD_mQGB8DdDxsOFVm1Z5gmjndwacynfWGd5WvKQRPoE28X_MfsA106Qi_QrGdeaiZV0iXfHN9EyhswCn0zxO1JKo4Cg4LuR_ra77_orGg-zmshy6iAEceSZdXfYejd_Wiix11-3nCzo4_fT06aabODE3SWm0bmYQAKBFcbkXJ8SATziCaXigBZMjWJuEKgHYiKqGilTFnZAMLBa3NkpN6yvZqX-EZ42iPFrA5RYeSAUQIolUmGutMkcsEacHe3ZLJX40AHB4dF6KpJ5p6oqmfaLpgH4iQfz8k7OzhAXKUnzjK_4ujFuzNLRt4PGu0i6ECbqiXKJF1a3DGBVvO-GM24_xN7S4G1G5BgNDCLp__jzW-YPfov0mJSvWS7W3XN_AKraNtfD0chD_UHBZj priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZKkRAXxFMsLxmJE1JK_YizPiBUClUF2j2x0t4ixx63UVunTbaI_kL-FjNJFhGpB66JNU4843l4xt8w9k5FGZyd55nDYBkDFItbyjiTaYIGMTLkvj_MWSzN8Up_W-frHbZtbzUuYHdraEf9pFbt-d6vq5tPuOE_UsSJ9vZDbBKBEUq1JyTlmewddldqpUngF6O3PyjmnLoaULs5qXRmtVoPec7bqUwsVQ_oP_FCpzWU_xilo4fswehN8oOB_Y_YDqTH7N5izJc_Yb-XFNie9NDSxAE-Vk6jveJ1GAqFoOOHX74v5QHvM-fDCR53HafSrdQQjjOnS_pUx9N2vE68pTN6QnXiTcsvYOPoVhKOQr0euEuBJ_BnvLu6dnSuwCk3wD31LEpIBclCaIYCnPMbogX1z_576KYKcBQif3bZ1Ei9Tqd1VVM7oKdsdfT1x-FxNrZuyLzWapNJLwRArMCGQsRQ7QcCIkTfDFWEdMEYL2wE0FZUSqjKyCoElBMDEd3RGLx6xnZTk-A54-iwRjDBVxZVBwjnRKHyKjc2j3Luwc_Y-y2byssBoaPEyIZ4WhJPS-JpOfJ0xj4TI_8OJHDt_kHTnpTjXi2l00pFX-wHAbrQ1gkNlY5Q5N5bJ-OMvd2KQYmbkVbRJcAFLSWqbF3kOOOMzSfyMZlx-ibVpz2styDEaGHmL_6D_Et2n36LjKhUr9jupr2G1-gdbao3vcz_ARfPFMA priority: 102 providerName: Scholars Portal |
Title | Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors |
URI | https://search.proquest.com/docview/2887475202 https://pubmed.ncbi.nlm.nih.gov/PMC10627168 https://doaj.org/article/2a433fc70d1e4749a14eb4fe75cc9a2f |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELbaHhAXxFOER2UkTkhJ6sd642MJlAqUiAOVelt57XG7auMNSYrEL-RvMePdoO6Viw-7XtvrGdsz48-fGXuvogzOzoqxQ2cZHRSLQ8o4M9ZEDWJkKHwO5iyW5vxCf70sLg-Y2Z-FyaB9XzeTdLuapOY6YyvXKz_d48Sm3xdzQdy6wsymh-ywVOqej97NvwVdXtBtYaIHZqexTcRWKNVESNqIsoNFKHP1DwzMITzy3npz9pg96g1Ffto16Ak7gPSUPVj0W-HP2J8l-axXmTWaOpf3oGhcingTOgwQbPn807elPOV5U7wLznG35YTKSi1RNHM6f08Qnc2WN4lvKPxOhE283fAV7BwdOMJcOGUH7lLgCfwN3_68cxQy4BT2556uI0pYChYLoe2wNbe_qSxofuX20CEU4Kgf_mbdNlh6k66buqGbfp6zi7PPP-bn4_5WhrHXWu3G0gsBEGuwoRQx1CeBOAbR7MLRL10wxgsbAbQVtRKqNrIOAVXAQERLMwavXrCj1CZ4yTjaohFM8LXFWQGEc6JURV0YW0Q58-BH7MNeTNW6I9-o0GkhmVYk04pkWvUyHbGPJMh_GYk3Oz9oN1dVrz2VdFqp6MuTIECX2jqhodYRysJ762QcsXd7NahwnFEvugTYoZXE2ViXBdY4YrOBfgxqHL5BBc6M3XuFffX_n75mD-lvadmU6g072m3u4C3aQ7v6OMcRMP1yKTBd6NlxHhB_AdtuF3Y |
link.rule.ids | 230,315,733,786,790,870,891,2115,24346,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGkIAX7ohyNRJPSG1nx3Hqx1GYClsrHjaxt8jXLerqlDZFgj_I3-KcXNDCG7zGiRM7n33O8fn8mZC3SeBOq0k61BAsQ4CiYEhJLYcCpUEkd6mtF3PmCzk7E5_P0_M9Iru9MDVp35piFK9Wo1hc1tzK9cqOO57Y-Mt8ylBbl8nJ-Aa5CQOWZ9ei9GYGTvH4giaJCTGYGocyol4hT0aMYypK9cxQrdbfczH7BMlrFufoHvnafWtDNFmOdpUZ2Z9_yTj-e2Puk7utE0oPm_IHZM_Hh-TWvE2zPyK_FhgPX9SK1PjjaEu4BjNHC9fwi_yWTj8cL_ghrRPuzcIf1VuKjK9Yovwzxb39SP_ZbGkR6QaX9lEMipYbuvKVxs1McBeYA0d1dDR6u6TbbzuNyxEUUwrU4lFHEWqBar0rG97O1Q-syxff6-_BDS6eAvbscl0WUHsRLwtT4ClCj8nZ0cfT6WzYnvgwtEIk1ZBbxrwPxiuXseDMgUP9QnDpYGbh2klpmQreC8VMwhIjuXEO4CV9AC82OJs8IfuxjP4poeDnBi-dNQpmHM-0ZlmSmlSqNPCJ9XZA3nUAyNeNsEcOARGiJUe05IiWvEXLgLxHiPy5ETW56wvl5iJvf2bOtUiSYLMDx7zIhNJMeCOCz1JrleZhQN50AMthDGMv6uihQ3MOM73IUnjjgEx6yOu9sV8CeKrVwDv8PPv_R1-T27PT-Ul-8mlx_JzcwZajeebJC7JfbXb-JfhdlXlVD7LfB1A23g |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUX3qjL00ickHa3dhJnfSxbVoWyqx6oVIlD5Me4jbbrLPtAgj_I32ImyaKGY6-J48TOZ8-M5_Nnxt4nQXqjR1nfYLCMAYrGIaWM6qckDaKkz1y9mDOdqZPz9MtFdtGyKtctrTI6Ww7i9WIQy6uaW7lcuOGOJzY8m44FaesKNRoufRjeZfdw0Ep9I1JvZuGMjjBoEpkYh-lhqCJpFspkICSlo3THFNWK_R03s0uSvGF1Jg_Z9933NmST-WC7sQP3-z8px9s16BF70Dqj_Kgp85jdgfiE7U_bdPtT9mdGcfFlrUxNP5C3xGs0d7z0Dc8I1nx8fDqTR7xOvDcLgNysOTG_YkUy0Jz2-BMNaLXmZeQrWuInUSherfgCNoY2NWEpNAuem-h5BDfn6x9bQ8sSnFIL3NGRRxFrwWrBVw1_5_oX1QXlz_p7aKMLcMSgmy-rEmsv41VpSzpN6Bk7n3z6Nj7ptyc_9F2aJpu-dEIABAva5yJ4e-hJxxBdO5xhpPFKOaEDQKqFTURilbTeI8wUBPRmg3fJc7YXqwgHjKO_G0B5ZzXOPCCMEXmS2UzpLMiRA9djH3YgKJaNwEeBgREhpiDEFISYokVMj30kmPwrSNrc9YVqdVm0P7SQJk2S4PJDLyDNU21ECjYNkGfOaSNDj73bgazAsUy9aCJghxYSZ_w0z_CNPTbqoK_zxu4dxFStCr7D0IvbP_qW7Z8dT4qvn2enL9l9ajhZaZm8Ynub1RZeo_u1sW_qcfYXZXQ5Xg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Next-generation+sequencing+identifies+CDKN2A+alterations+as+prognostic+biomarkers+in+recurrent+or+metastatic+head+and+neck+squamous+cell+carcinoma+predominantly+receiving+immune+checkpoint+inhibitors&rft.jtitle=Frontiers+in+oncology&rft.au=Xue%2C+Liqiong&rft.au=Tang%2C+Wenbo&rft.au=Zhou%2C+Jiuli&rft.au=Xue%2C+Junli&rft.date=2023-10-23&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=13&rft.spage=1276009&rft.epage=1276009&rft_id=info:doi/10.3389%2Ffonc.2023.1276009&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon |